Research Areas

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC1027	Bortezomib (Velcade,MG-341,PS-341) Featured	Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
DC8883	BP897 Featured	BP897 is a partially selective D3 dopamine receptor agonist.
DC8392	BQ-123 Featured	BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
DC7097	Cebranopadol(GRT-6005) Featured	branopadol(GRT-6005) is a novel first in class compounds with potent agonist activity on ORL-1 (opioid receptor like -1) and the well established mu opioid receptor.
DC2019	Brivanib (bms-540215) Featured	Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.
DC11038	Bryostatin 1 Featured	Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).
DC7378	BSI-201	BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).
DCAPI1140	Bumetanide Featured	Bumetanide
DC8089	BVT 2733(BVT.2733) Featured	BVT 2733 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor,protecting osteoblasts against endogenous glucocorticoid induced dysfunction.
DC8278	BVT-14225 Featured	BVT 14225 is a new selective 11b-HSD1 inhibitor, it belongs to a class of arylsulfonamidothiazoles with in vitro and in vivo antidiabetic effects
DC7675	BX-471（ZK 811752） Featured	BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
DC10864	C188-9 Featured	C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.
DC10648	CA4948-Analog Featured	CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i
DC4186	Cabazitaxel	Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid.
DC9266	Cabozantinib S-malate Featured	Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
DC5068	Idelalisib (CAL-101,GS-1101) Featured	CAL-101 is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ thanp110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
DCAPI1559	Calcifediol Featured	Calcifediol is a major circulating metabolite of vitamin D3, acting as a competitive inhibitor with an apparent Ki of 3.9 μM, suppresses PTH secretion and mRNA (ED50=2 nM).
DC3111	Canagliflozin Featured	Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively.
DC9185	Candesartan cilexetil Featured	Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
DC9142	Candesartan	Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
DC3138	Canertinib dihydrochloride Featured	Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities.
DC7005	Cangrelor free acid Featured	Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggrega
DC9095	Carboplatin Featured	Carboplatin is a chemotherapy drug by binding to DNA and interfering with the cell's repair mechanism.
DC1002	Carfilzomib (PR-171) Featured	Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells,showed potent activity against COVID-19(SARS-COV-2).
DC7990	Cariporide	Cariporide is a selective Na+/H+ exchanger isoform 1 (NHE1) inhibitor (IC50 values are 0.05, 3 and 1000 μM for NHE1, NHE3 and NHE2 respectively).
DC11354	Carteolol (hydrochloride)	Carteolol is an antagonist of β-adrenergic receptors (Kd = 13 nM).
DCAPI1497	Cancidas Featured	Caspofungin is a semi-synthetic analogue of pneumocandin B0 with improved water solubility, a significant limitation in the development of the echinocandin class as pharmaceuticals. Caspofungin acts by inhibition of the synthesis of β (1,3)-D-glucan, an e
DC8482	CAY10415(MSDC-0160) Featured	CAY10415 is a potent, antidiabetic drug of the TZD structural class.
DC4160	CB-03-01 Featured	CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.
DC11709	CB-1158	CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM.

Research Areas

Customized Consultation X

Your information is safe with us. * Required Fields.